UPDATE: Oppenheimer Downgrades Optimer Pharmaceuticals to Perform on Near-Term Outlook
Oppenheimer reduced its rating on Optimer Pharmaceuticals (NASDAQ: OPTR) from Outperform to Perform.
Oppenheimer noted, "We are downgrading shares of OPTR on the deceleration of DIFICID script growth which may be partially attributable to the availability of generic Vancocin. Longer term, scripts may be adversely impacted post expiration of the CBST co- promote agreement in 4/2013."
Optimer Pharmaceuticals closed at $11.46 on Monday.
Latest Ratings for OPTR
|Jul 2013||Canaccord Genuity||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.